{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T04:10:28Z","timestamp":1759551028054,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.reumae.2025.501946","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:30:48Z","timestamp":1759548648000},"page":"501946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile"],"prefix":"10.1016","volume":"21","author":[{"given":"Marcos","family":"Cruces Olivar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan D.","family":"Burboa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda M.","family":"G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2025.501946_bib0105","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1521-6942(03)00041-X","article-title":"Co-morbidity in rheumatoid arthritis","volume":"17","author":"Mikuls","year":"2003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.reumae.2025.501946_bib0110","series-title":"Protocolo Artritis Reumatoide Activa Refractaria A Tratamiento Habitual \u2013 Ley 20.850 Ministerio De Salud Chile","year":"2019"},{"key":"10.1016\/j.reumae.2025.501946_bib0115","first-page":"279","article-title":"2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis","volume":"11","author":"Sanmarti","year":"2015","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2025.501946_bib0120","first-page":"117","article-title":"First Latin American position paper on the pharmacological treatment of rheumatoid arthritis","volume":"45","author":"Cardiel","year":"2006","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.reumae.2025.501946_bib0125","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3899\/jrheum.091466","article-title":"Golimumab for rheumatoid arthritis","volume":"37","author":"Singh","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.reumae.2025.501946_bib0130","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.clinthera.2014.06.018","article-title":"Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis","volume":"36","author":"Kaur","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.reumae.2025.501946_bib0135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.reuma.2012.02.010","article-title":"Terapia biol\u00f3gica: sobrevida y seguridad en padecimientos reum\u00e1ticos. Resultados del Registro Nacional Biobadamex 1.0","volume":"8","author":"Ventura-R\u00edos","year":"2012","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2025.501946_bib0140","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/acr.22788","article-title":"Twelve-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: real-life data from a local registry","volume":"68","author":"Favalli","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.reumae.2025.501946_bib0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/CEOR.S124381","article-title":"Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data","volume":"9","author":"Brodszky","year":"2017","journal-title":"Clin Econ Outcomes Res"},{"key":"10.1016\/j.reumae.2025.501946_bib0150","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.reuma.2018.08.009","article-title":"Safety and survival associated with biologic therapies: first report of the Biobadaguay on the Paraguayan-Uruguayan registry of adverse events with biologic therapies","volume":"16","author":"De Abreu","year":"2020","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.reumae.2025.501946_bib0155","doi-asserted-by":"crossref","first-page":"927179","DOI":"10.3389\/fphar.2022.927179","article-title":"Real-world effectiveness of biological therapy in patients with rheumatoid arthritis: systematic review and meta-analysis","volume":"13","author":"Castro","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.reumae.2025.501946_bib0160","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1007\/s12325-023-02607-w","article-title":"Real-world data of adherence and drug survival of biologics in treatment-na\u00efve and treatment experienced adult patients with rheumatoid arthritis","volume":"40","author":"Rosenberg","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.reumae.2025.501946_bib0165","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1007\/s10067-024-07070-8","article-title":"Subsequent biologic and targeted synthetic disease modifying antirheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis","volume":"43","author":"Novella","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.reumae.2025.501946_bib0170","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria. An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.reumae.2025.501946_bib0175","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.reumae.2025.501946_bib0180","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc Ser B (Meth)"},{"key":"10.1016\/j.reumae.2025.501946_bib0185","unstructured":"The R Project for Statistical Computing. (s. f.-b) [cited 2024 Aug]. Available from: https:\/\/www.r-project.org\/."},{"key":"10.1016\/j.reumae.2025.501946_bib0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/acr2.1010","article-title":"Persistence of tofacitinib in the treatment of rheumatoid arthritis in open-label long-term extension studies up to 9.5 years","volume":"1","author":"Pope","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.reumae.2025.501946_bib0195","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3904\/kjim.2023.297","article-title":"Drug retention of biologic and targeted synthetic disease-modifying antirheumatic drugs in Korean patients with seropositive rheumatoid arthritis","volume":"39","author":"Lee","year":"2024","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.reumae.2025.501946_bib0200","article-title":"Switching and discontinuation pattern of biologic disease-modifying antirheumatic drugs and tofacitinib for patients with rheumatoid arthritis in Taiwan","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574325001303?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574325001303?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T03:31:27Z","timestamp":1759548687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574325001303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2173574325001303"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2025.501946","relation":{},"ISSN":["2173-5743"],"issn-type":[{"value":"2173-5743","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival of first line biological and targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis in Chile","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2025.501946","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Reumatolog\u00eda (SER), Colegio Mexicano de Reumatolog\u00eda (CMR) and Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501946"}}